Navilyst Medical, an AngioDynamics company, received FDA clearance for its BioFlo Port with Endexo technology. The port is designed to be placed under the skin for long term delivery of medication, chemotherapy, blood draws, or for IV feeding. The Endexo technology prevents the gathering of platelets and thrombi on the surface of the port catheter thanks to a special non-eluting integral polymer.
The company hopes the device will help reduce the necessity for prescribing blood thinners, antibiotics, and antimicrobials for patients with such ports.
In-vitro blood loop model test results show that on average the BioFlo Port catheter had 96% less thrombus accumulation on its surface compared to non-coated conventional port catheters (based on platelet count).2 The BioFlo Ports are also available with PASV Valve Technology, AngioDynamics’ patented valve designed to automatically resist backflow and reduce blood reflux on the inside of the catheter.